Table 2.
Anti-spike Antibody Concentration and Seroconversion Rates in Solid Tumour and Hematologic Patients following Two Doses of COVID-19 Vaccine, According to Treatment Type.
| Participant Group Treatment Type |
Patients (n) |
Anti-S Concentration, BAU/mL | Seroconversion Rate per Cutoff, n (%) |
p-Value (If < 0.05) |
|||
|---|---|---|---|---|---|---|---|
| Mean (±SD) | Median | 35.2 BAU/mL | 140.8 BAU/mL | 281.6 BAU/mL | |||
| Healthy Controls | 35 | 382.4 (9.4) | 384 | 35 (100) | 35 (100) | 35 (100) | |
| Solid Tumour | 76 | 265.8 (145.7) * | 384 | 64 (84) | 56 (74) | 45 (59) | * < 0.0001 * < 0.01 |
| No systemic therapy | 14 | 315 (156) | 381 | 14 (100) | 12 (86) | 10 (64) | |
| Cytotoxic chemotherapy + | 30 | 195 (156) */# | 154 | 23 (77) | 17 (57) | 15 (50) | |
| Immunotherapy alone | 14 | 300 (138) | 384 | 14 (100) | 11 (79) | 10 (72) | |
| Targeted therapy alone | 12 | 331 (126) | 381 | 11 (92) | 10 (83) | 10 (83) | |
| Hormonal therapy alone | 6 | 358 (64) | 384 | 6 (100) | 6 (100) | 5 (83) | |
| Hematologic | 40 13 11 16 |
168.2 (172.9) * 340 (116) 41 (113) */** 117 (144) */** |
72 384 4 48 |
21 (53) 12 (93) 1 (9) 8 (50) |
17 (43) 12 (93) 1 (9) 4 (25) |
15 (38) 11 (86) 1 (9) 3 (19) |
* < 0.0001 */** < 0.01 */** < 0.01 |
| No active therapy | |||||||
| Anti-CD20 therapy | |||||||
| Systemic therapy(non-anti-CD20) | |||||||
* indicates comparison to healthy controls, using one-way ANOVA test with post-hoc Tukey test. ** indicates comparison to no therapy group within the same cancer type, using one-way ANOVA test with post-hoc Tukey test. # p = 0.056 if directly comparing cytotoxic chemotherapy to no therapy, and p = 0.24 when using Tukey test that accounts for multiple comparisons. No statistical differences between each treatment to no systemic therapy in the solid cancer group. + Cytotoxic chemotherapy alone or cytotoxic chemotherapy plus immunotherapy.